Breakthrough in Mental Health: SciSparc and Clearmind Partnership

Innovative Collaboration in Mental Health Treatment

This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care.

SciSparc Ltd. (Nasdaq: SPRC), a notable specialty clinical-stage pharmaceutical company, has announced the publication of an international patent application in conjunction with Clearmind Medicine Inc. (Nasdaq: CMND), a biotechnology company devoted to novel therapeutic solutions.

Developing Transformative Therapies

The collaboration centers around the pioneering combination of Ibogaine with N-Acylethanolamines, a combination designed to tackle significant mental health challenges.

Ibogaine is derived from the root of the Tabernanthe iboga shrub found primarily in Western and Central Africa. This component is renowned for its potential efficacy in treating various substance use disorders, including opioid and cocaine use disorders. The promising results from human clinical trials highlight Ibogaine's potential as an effective anti-addictive agent.

Ongoing Research and Patent Filings

As the partnership continues to develop innovative therapeutic solutions, both SciSparc and Clearmind are focusing on the integration of psychedelic molecules with N-acylethanolamines, such as Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind with authorities including the U.S. Patent and Trademark Office.

Why Ibogaine?

Research has indicated that Ibogaine may have transformative effects in combating addiction. Its unique properties present a radical shift in addressing long-standing issues associated with substance use disorders.

The Role of N-Acylethanolamines

N-acylethanolamines are naturally occurring lipid compounds known for their neuroprotective properties. Their inclusion in therapy may enhance the efficacy and safety of the treatment protocols being explored by SciSparc and Clearmind.

About SciSparc Ltd. and Clearmind Medicine Inc.

SciSparc Ltd. operates within the clinical pharmaceutical landscape and is focused on developing therapies for disorders affecting the central nervous system. Its impressive drug development programs include treatments targeting Tourette Syndrome, Alzheimer's disease, and autism.

Clearmind Medicine Inc., a clinical-stage psychedelic pharmaceutical biotech firm, is focused on creating therapeutic solutions that address prevalent health issues like alcohol use disorder. The company is expanding its intellectual property with nineteen patent families comprising 29 granted patents and is actively pursuing additional patents as needed.

Investor Relations and Contact Information

SciSparc is committed to transparency and effective communication with its investors. For inquiries, investors can reach out to the company directly. For further details, individuals can send an email to IR@scisparc.com or call at +972-3-6167055.

Frequently Asked Questions

What is the main focus of SciSparc's collaboration with Clearmind?

The collaboration primarily focuses on developing innovative therapies that combine Ibogaine with N-acylethanolamines to address mental health and addiction issues.

What are N-acylethanolamines?

N-acylethanolamines are lipid compounds with neuroprotective properties, which are being explored in combination with Ibogaine for enhanced therapeutic effects.

How does Ibogaine work in treating addiction?

Ibogaine has shown potential in treating various substance use disorders by altering brain chemistry, which may help reduce withdrawal symptoms and cravings.

How many patents have been filed in relation to this collaboration?

Thirteen patents related to the SciSparc and Clearmind collaboration have been filed with relevant patent authorities.

What other conditions is SciSparc targeting with its therapies?

SciSparc is also developing treatments for Tourette Syndrome, Alzheimer's disease, and autism, focusing on innovative cannabinoid-based solutions.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.